We are live on ! Find out more
ATXI

Avenue Therapeutics, Inc. Common Stock
ATXI

Delisted

ATXI was delisted on the 18th of March, 2025.

Back to rankings

11 hedge funds and large institutions have $849K invested in Avenue Therapeutics, Inc. Common Stock in 2023 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

59% more capital invested

Capital invested by funds: $533K → $849K (+$317K)

50% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 2

15% less funds holding

Funds holding: 13 → 11 (-2)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 2

Holders
11
Holders Change
-2
Holders Change %
-15.38%
% of All Funds
0.17%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
3
Reduced
2
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
+$300K
2
Geode Capital Management
Geode Capital Management
Massachusetts
+$45.2K
3
SAM
Shikiar Asset Management
New York
+$16.5K

Top Sellers

Rank Fund Capital Flow
1
IWP
Icon Wealth Partners
Texas
-$46.6K
2
Renaissance Technologies
Renaissance Technologies
New York
-$19K
3
TRCT
Tower Research Capital (TRC)
New York
-$2.64K
4
Bank of New York Mellon
Bank of New York Mellon
New York
-$494

ATXI Hedge Fund Activity: Q2 2023 in Review

11 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Avenue Therapeutics, Inc. Common Stock (ATXI) for Q2 2023, worth a combined $849K — up 59% from $533K a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of ATXI and 0 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 3 added.

The largest buyer was Sabby Management, adding an estimated $300K. The largest seller was Icon Wealth Partners, exiting entirely with an estimated $46.6K sold.

  • 11 institutional investors held Avenue Therapeutics, Inc. Common Stock (ATXI) as of Q2 2023, down from 13 in Q1 2023.
  • Funds reported $849K of Avenue Therapeutics, Inc. Common Stock stock for Q2 2023, up 59% quarter-over-quarter.
  • 0 funds opened new Avenue Therapeutics, Inc. Common Stock positions in Q2 2023 and 2 closed out, a net change of -2 holders.
  • The largest Avenue Therapeutics, Inc. Common Stock buyer in Q2 2023 was Sabby Management, an estimated $300K added.
  • The largest Avenue Therapeutics, Inc. Common Stock seller in Q2 2023 was Icon Wealth Partners, an estimated $46.6K sold.

Based on aggregated 13F filings for Q2 2023.